Overview

A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

Status:
Not yet recruiting
Trial end date:
2028-07-04
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation and durability/revaccination evaluation of the selected RSV preF-based vaccine formulation in participants aged greater than or equal to (>=) 60 years in stable health.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Janssen Vaccines & Prevention B.V.